About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring ...
Dr John Levine, Chair of the BMT CTN Steering Committee and Professor of Internal Medicine and Pediatrics, Icahn School of Medicine at Mount Sinai, New York said: “We are delighted to be partnering ...
MISSISSAUGA, Ontario, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September ...
Jefferies, BofA Securities and Cantor are acting as joint book-running managers for the offering. LifeSci Capital and Oppenheimer & Co. are acting as co-lead managers for the offering. H.C. Wainwright ...
IRVING, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CHRISTUS Health has been recognized as a national 2025 “Most Wired” health provider for digital transformation that influences quality and ...
Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program The ability to attract seasoned ophthalmology leaders highlights the ...
Seren Advanced Dentistry Oxnard today formally announced the introduction of biomimetic conservative dentistry as part of its restorative care offerings. The announcement marks a structured update to ...
As of September 30, 2025, the Company had $48.6 million of outstanding indebtedness with a weighted-average annual interest rate of 5.0% and a weighted-average maturity of approximately 16 years. For ...
The Bank of New York Mellon serves as depositary (the “Depositary”) for the Company’s ADS facility. Each ADS represents one ordinary share. GENFIT intends to terminate the Deposit Agreement, dated ...
RxSight’s management is scheduled to present on Wednesday, December 3, 2025, at 12:00 p.m. Eastern Time. A live and archived webcast of the presentation will be available at: https://investors.rxsight ...
Presentation materials will also be posted on the Investor Relations section of the DLH website prior to the commencement of the conference call. A digital recording of the conference call will be ...
GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback